UNSPSC 51332527: Trifluperidol hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C22H23F4NO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UIC8RB6P81, chemically known as 4-fluoro-4-(4-hydroxy-4-(alpha,alpha,alpha-trifluoro-m-tolyl)piperidino)butyrophenone but more generally known as trifluperidol hydrochloride, which bears US NIH Compound Identifier 5567. European Medicines Agency schedules Trifluperidol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04957MIG.

Most nations, for tariff and trade purposes, schedule trifluperidol hydrochloride under HS 29333999 and SITC 51574. As of Q4 2014, TRIFLUPERIDOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: C1CC(CC(C1)C(F)(F)F)C2(CCN(CC2)CCCC(=O)C3CCC(CC3)F)O.CL.

UNSPSC 51332527 Trifluperidol hydrochloride is a Commodity code that nominally names a specific antipsychotic pharmaceutical, but recent state and local solicitations show little activity directly aligned with this narrow product definition. The recent opportunities block contains three entries: a Seminole County, Florida IFB for naloxone and drug deactivation systems (a harm-reduction public health product unrelated to trifluperidol); a Texas Health and Human Services Commission RFI exploring direct-to-manufacturer prescription programs without naming specific drugs; and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers. None of these solicitations names trifluperidol hydrochloride or reference this code's narrow scope. The code shows minimal relevant recent activity; when state and local governments do solicit pharmaceutical products, they appear to use broader commodity codes or cooperative purchasing vehicles rather than narrow single-drug codes.

Geographic activity is concentrated in Florida, Texas, and Minnesota based on the three recent opportunities, but the mismatch between the code's nominal scope and what is actually being solicited suggests this Commodity code does not meaningfully track state and local procurement of trifluperidol hydrochloride itself. The Seminole County naloxone purchase (IFB60459723LAS, due July 26, 2023) targets community health initiatives with annual volumes of 1,900 units of naloxone and 800 safe drug deactivation systems delivered quarterly to Sanford, Florida. The MMCAP RFP (S1070000015802, due March 26, 2026) is the most relevant pharmaceutical procurement shown, but it covers generic multi-source products and OTC items distributed across multiple states through three authorized wholesalers, with awards effective July 1, 2026. Neither opportunity nor the Texas RFI address the specific product named in this code, indicating the code may be misapplied to state and local procurement activity or sees no current solicitations for this particular pharmaceutical.